Address
Email address
Phone number
Website
https://www.icosagen.eeKoduleht - IcosagenMuudame ideed reaalsuseks Icosagen on pühendunud Eesti biotehnoloogiaettevõte, mis tegeleb terapeutiliste antikehade arendamise ja diagnostiliste rekombinantsete valkude tootmisega imetajate rakkudes nii teadusuuringute kui ka in vitro diagnostika tarbeks. Loe lisaks Meist Teenused Klientide tagasiside “Fast responses, great flexibility, transparency, collaborative spirit, high quality” Ridgeline Kliki siia”Fast reply, quality of reports, good product profile” Pharis Biofarmaceuticals […]
Name
Icosagen AS
Registry code
10565884
VAT number
EE100573055
Type
AS - Joint Stock Company
Status
Registered
Foundation date
27.08.1999 (25)
Financial year
01.01-31.12
Capital
192 448.00 €
Activity
72191 - Other research and experimental development on natural sciences and engineering 96099 - Other service activities 72111 - Research and experimental development on biotechnology
-
-
-
-
-
-
-
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Amplikon OÜ 12860392 | 96% - 184 838.40 EUR | - | - | Shareholder |
| Mart Ustav
| - | Board member | - | Founder |
| Mart Ustav
| - | Board member | - | |
| Ene Talpsep
| - | - | - | Board member |
| Richard Villems
| - | - | - | Board member |
| Ain Laving
| - | - | - | Founder |
| Elve Raukas
| - | - | - | Founder |
| Marika Mikelsaar
| - | - | - | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| ICO Park OÜ 12401945 | 100% - 2 502.00 EUR | - | - | Founder |
| Icosagen Cell Factory OÜ 11107818 | 100% - 11 504.00 EUR | - | - | Founder |
| OÜ Icosagen Toxicology Services 12402287 | 40% - 1 000.00 EUR | - | - | Founder |
| SYNLAB Eesti OÜ 11107913 | - | - | - | Founder |
| aktsiaselts Biotehnoloogia Park Kinnisvara 10834232 | - | - | - | Founder |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q4 | 354 903.12 € | 144 347.23 € | 120 547.68 € | 38 |
| 2024 Q3 | 487 816.79 € | 172 698.12 € | 124 809.08 € | 37 |
| 2024 Q2 | 503 046.27 € | 140 899.3 € | 108 634.43 € | 38 |
| 2024 Q1 | 755 727.08 € | 213 876.25 € | 158 927.07 € | 32 |
| 2023 Q4 | 493 171.14 € | 146 801.14 € | 106 943.01 € | 31 |
| 2023 Q3 | 644 958.01 € | 167 489.75 € | 108 939.92 € | 32 |
| 2023 Q2 | 312 229.78 € | 113 820.42 € | 106 726.26 € | 31 |
| 2023 Q1 | 1 253 221.81 € | 136 474.36 € | 138 949.78 € | 33 |
| 2022 Q4 | 321 851.17 € | 89 605.59 € | 90 365.87 € | 30 |
| 2022 Q3 | 376 835.42 € | 91 642.1 € | 93 200.11 € | 31 |
| 2022 Q2 | 316 313.26 € | 86 231.84 € | 84 149.06 € | 31 |
| 2022 Q1 | 747 059.21 € | 115 928.44 € | 122 481.58 € | 30 |
| 2021 Q4 | 1 503 788.96 € | 66 955.7 € | 69 694.43 € | 31 |
| 2021 Q3 | 688 896.47 € | 63 119.21 € | 72 630.12 € | 31 |
| 2021 Q2 | 700 350.46 € | 74 917.16 € | 60 313.95 € | 32 |
| 2021 Q1 | 542 830.46 € | 85 833.62 € | 73 644.84 € | 23 |
| 2020 Q4 | 747 667.97 € | 83 331.75 € | 61 866.77 € | 22 |
| 2020 Q3 | 733 661.32 € | 67 866.8 € | 59 595.17 € | 27 |
| 2020 Q2 | 611 750.64 € | 72 848.69 € | 49 196.29 € | 24 |
| 2020 Q1 | 294 857.56 € | 74 072.7 € | 59 557.54 € | 23 |
